Free Trial

Promis Neurosciences (PMN) Stock Price, News & Analysis

Promis Neurosciences logo
$0.39 -0.01 (-3.01%)
Closing price 07/11/2025 03:56 PM Eastern
Extended Trading
$0.40 +0.00 (+1.18%)
As of 07/11/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Promis Neurosciences Stock (NASDAQ:PMN)

Key Stats

Today's Range
$0.39
$0.42
50-Day Range
$0.39
$0.64
52-Week Range
$0.38
$2.28
Volume
141,341 shs
Average Volume
83,328 shs
Market Capitalization
$12.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Buy

Company Overview

Promis Neurosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

PMN MarketRank™: 

Promis Neurosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 551st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Promis Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Promis Neurosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Promis Neurosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Promis Neurosciences are expected to grow in the coming year, from ($0.24) to ($0.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Promis Neurosciences is -7.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Promis Neurosciences is -7.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Promis Neurosciences has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Promis Neurosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.61% of the float of Promis Neurosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Promis Neurosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Promis Neurosciences has recently decreased by 0.07%, indicating that investor sentiment is improving.
  • Dividend Yield

    Promis Neurosciences does not currently pay a dividend.

  • Dividend Growth

    Promis Neurosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.61% of the float of Promis Neurosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Promis Neurosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Promis Neurosciences has recently decreased by 0.07%, indicating that investor sentiment is improving.
  • News Sentiment

    Promis Neurosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Promis Neurosciences this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Promis Neurosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.11% of the stock of Promis Neurosciences is held by insiders.

  • Percentage Held by Institutions

    50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Promis Neurosciences' insider trading history.
Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

PMN Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
See More Headlines

PMN Stock Analysis - Frequently Asked Questions

Promis Neurosciences' stock was trading at $0.9478 on January 1st, 2025. Since then, PMN stock has decreased by 58.8% and is now trading at $0.3904.

Promis Neurosciences (NASDAQ:PMN) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.07.

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Exscientia (EXAI) and Trimble (TRMB).

Company Calendar

Last Earnings
5/12/2025
Today
7/12/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMN
CIK
1374339
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$3.00
Potential Upside/Downside
+1,052.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$2.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-186.19%
Return on Assets
-98.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.36
Quick Ratio
3.36

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
32,690,000
Free Float
30,692,000
Market Cap
$12.76 million
Optionable
Not Optionable
Beta
-0.10
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:PMN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners